4D Molecular Therapeutics proposes $100M stock offering
4D Molecular Therapeutics (NASDAQ:FDMT) on Thursday commenced an underwritten public offering of $100.0 million of shares of its common stock.
The company also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million shares.
All of the shares in the proposed offering are to be sold by the company.
Goldman Sachs, BofA Securities and Evercore ISI are acting as joint book-running managers for the proposed offering.
Chardan is acting as lead manager for the proposed offering.